IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

April 29, 2024

Study Completion Date

April 29, 2024

Conditions
Advanced Solid TumoursSmall Cell Lung Cancer
Interventions
DRUG

IMP4297(senaparib)

The dose levels will be escalated following a modified 3+3 dose escalation scheme.

Trial Locations (21)

100

National Taiwan University Hospital, Taipei

333

Chang Gung Medical Foundation Linko, Taoyuan District

404

China Medical University Hospital, Taichung

704

National Cheng Kung University Hospital, Tainan City

2148

Blacktown Hospital, Blacktown

2640

Border Medical Oncology, Albury

2800

Orange Hospital, Orange

2864

Chungbuk National University Hospital, Cheongju-si

3199

Peninsula Health Frankston Hospital, Frankston

16247

The Catholic university of Korea, st. Vincent's Hospital, Gyeonggi-do

37203

Sarah Cannon Research Institute - Tennessee Oncology, Tennessee City

43219

Mark H. Zangmeister Center, Columbus

44718

Gabrail Cancer Researh Center, Canton

60805

GenHarp Clinical Solutions, Evergreen Park

73657

Chi Mei Medical Center, Tainan City

100142

Beijing Cancer Hospital, Beijing

130000

Jilin Cancer Hospital, Jilin

200032

Fudan University Shanghai Cancer Center, Shanghai

430079

Hubei Cancer Hospital, Wuhan

03722

Yonsei university health system, Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY